Clinical trials: Tinea Pedis
Tinea Pedis
SINGLE-APPLICATION TERBINAFINE HYDROCHLORIDE (1%) TOPICAL LIQUID SOLUTION VERSUS A SINGLE-APPLICATION BUTENAFINE HYDROCHLORIDE (1%) TOPICAL LIQUID SOLUTION FOR THE TREATMENT OF TINEA PEDIS
Tinea pedis or athlete's foot is the most common fungal infection worldwide, caused by infection of the feet with dermatophytes such as Trichophyton rubrum, Trichophyton interdigitale (formerly Trichophyton mentagrophytes), and…
- Trial name
- NCT03999437
- Testing
- TERBINAFINE HYDROCHLORIDE (1%), BUTENAFINE HYDROCHLORIDE (1%), Vehicle Control
- Where
- Philippines
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- United Laboratories
Tinea Pedis
Cumulative Irritation Test
The purpose of this study is to determine the cumulative irritation potential of the products listed by the Sponsor.
- Trial name
- NCT00781664
- Testing
- AN2718, Sodium Lauryl Sulfate
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Pfizer
Tinea Pedis
SB208 for the Treatment of Tinea Pedis
This is a phase 2, multi-center, double-blind, randomized, vehicle-controlled study to be conducted in non immunocompromised adult subjects with interdigital tinea pedis.
- Trial name
- NCT02860052
- Testing
- SB208 2%, SB208 4%, SB208 16%
- Where
- Dominican Republic
- Volunteers
- 222 people
- Sponsor
- Novan, Inc.
Tinea Pedis
Evaluate Safety and Efficacy of Naftifine Hydrochloride Gel 2% and Naftin® Gel 2% in Tinea Pedis
To compare the efficacy and safety of the test formulation Naftifine Hydrochloride Gel 2% to Naftin® (Naftifine Hydrochloride) Gel 2%
- Trial name
- NCT02335255
- Testing
- Naftifine Hydrochloride Gel 2%, Naftin® Gel 2%
- Volunteers
- 1,519 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Tinea Pedis
A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Moderate - Severe Interdigital Tinea Pedis
The purpose of this study is to determine if the novel oral agent VT-1161 is safe and effective in treating patients with moderate - severe tinea pedis (also referred to as athletes foot).
- Trial name
- NCT01891305
- Testing
- VT-1161
- Where
- 7 sites in United States
- Volunteers
- 50 people
- Sponsor
- Viamet
Tinea Pedis
Three-Arm Trial of Novel Treatment for Tinea Pedis
This is a three-arm randomized controlled trial to assess the efficacy of an experimental treatment in the treatment of tinea pedis (athlete's foot).
- Trial name
- NCT03135912
- Testing
- Experimental Drug SESC 01, Terbinafine Hydrochloride
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- South End Skin Care
Tinea Pedis
A Study to Evaluate Efficacy and Safety of Three W0027 Regimens in the Treatment of Moccasin Type Tinea Pedis (MTTP)
In this phase Ib, multi-centre, randomized, double-blind, placebo-controlled parallel group study, 120 subjects with moccasin type tinea pedis (MTTP) will be enrolled at approximately 11 centres in the USA, Canada and Australia.
- Trial name
- NCT00509275
- Testing
- W0027
- Where
- 9 sites in United States, Australia
- Volunteers
- 120 people
- Sponsor
- Stiefel, a GSK Company
Tinea Pedis
BE Study of Naftifine HCL
The current study was randomized, double blind, placebo-controlled, prospective, multicenter, comparative therapeutic equivalence study. The study duration for each patient was 6 weeks: Following were the visit details.
- Trial name
- NCT02633813
- Testing
- Naftifine hydrochloride 2%, Naftin® 2% (Naftifine hydrochloride 2%)
- Where
- 14 sites in United States, Dominican Republic
- Volunteers
- 693 people
- Sponsor
- Genzum Life Sciences
Tinea Pedis
Evaluate the Safety and Efficacy of Naftifine Hydrochloride Cream 2% and Naftin® Cream 2% in Patients With Tinea Pedis
The objective of this study is to compare the efficacy and safety of the test formulation of Naftifine Hydrochloride Cream 2% to Naftin® (Naftifine Hydrochloride) 2% Cream in a 6 week study in patients with tinea pedis.
- Trial name
- NCT02132260
- Testing
- Naftifine Hydrochloride Cream 2%, Naftin® (Naftifine Hydrochloride) Cream 2%
- Volunteers
- 890 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Tinea Pedis
Evaluate the Safety & Bioequivalence of a Generic Butenafine Cream & Lotrimin Ultra® & Compare Both to a Vehicle Control in Treatment of Interdigital Tinea Pedis
The primary objective of this study is to determine the comparability of the safety and efficacy of a generic Butenafine Hydrochloride Cream, 1% (test product) and Lotrimin Ultra® (the reference listed drug) in subjects with…
- Trial name
- NCT01580878
- Testing
- Butenafine Hydrochloride Cream, 1%, Lotrimin Ultra®, Butenafine Vehicle
- Volunteers
- 707 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Tinea Pedis
Non-inferiority Phase III Trial Comparing Dapaconazole Cream 2% With Ketoconazole Cream 2% in Patients With Tinea Pedis
This is a non-inferiority, Phase III, open-label, randomized, parallel trial to evaluate the new intervention Dapaconazole cream 2% versus Ketoconazole cream 2% in patients with Tinea pedis.
- Trial name
- NCT02606383
- Testing
- Dapaconazole, Ketoconazole
- Where
- Brazil
- Sponsor
- Biolab Sanus Farmaceutica
Tinea Pedis, Tinea Cruris
Pharmacokinetic Study of Pediatric Subjects With Tinea Cruris and Tinea Pedis
This study is being done to see how the body is affected when a study drug is applied to both feet if the subject has athlete's foot or to both feet and the groin area if the subject has both athlete's foot and jock itch.
- Trial name
- NCT01712360
- Testing
- NAFT500 (pediatric), NAFT600 (pediatric), NAFT500 (adult)
- Where
- 4 sites in United States, Dominican Republic and 1 more
- Volunteers
- 56 people
- Sponsor
- Merz North America, Inc.
Tinea Pedis
Comparative Safety and Efficacy Study of New Bifonazol Spray vs Terbinafine Solution vs Placebo
The study shall prove whether 6 consecutive doses of Bifonazole spray show comparable efficacy to a Terbinafine solution applied once.
- Trial name
- Porsche (NCT01013909)
- Testing
- Bifonazole spray once daily, Bifonazole spray twice daily, Lamisil Once
- Where
- 4 sites in Germany
- Volunteers
- 220 people
- Sponsor
- Bayer
Interdigital Tinea Pedis
Clinical Equivalence of Two Generic Butenafine Hydrochloride 1% Creams as Compared to Lotrimin Ultra Cream in Patients With Interdigital Tinea Pedis
To demonstrate comparable safety and efficacy of Taro Pharmaceuticals, Inc butenafine hydrochloride cream 1% test product and Lotrimin Ultra cream (reference listed drug) in the treatment of interdigital tinea pedis, and to show…
- Trial name
- BNF-0909 (NCT01119742)
- Testing
- Butenafine Hydrochloride 1%, Butenafine Hydrochloride 1% B, Vehicle A
- Volunteers
- 428 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Tinea Pedis
Evaluate the Clinical Equivalence of Two Naftifine HCl 1% Creams in Patients With Interdigital Tinea Pedis
The objective of this study is to evaluate the efficacy and safety of the test formulation of Naftifine HCl Cream 1% (Taro Pharmaceuticals Inc.) as compared to the already marketed formulation Naftin® (Naftifine HCl) 1% Cream…
- Trial name
- NCT01580891
- Testing
- Naftifine HCl Cream 1%, Naftin® (Naftifine HCl) Cream 1%
- Volunteers
- 1,053 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Tinea Pedis
An Efficacy Study of a New Formulation of Ketoconazole 2% Cream in Patients With Tinea Pedis, Commonly Known as Athlete's Foot
The purpose of this study is to determine if a new formulation of ketoconazole 2% cream is as effective as a current formulation of ketoconazole 2% cream (Nizoral) compared with placebo in treating patients with Tinea pedis, a…
- Trial name
- NCT01110330
- Testing
- Ketoconazole 2% cream (formulation F012) (Nizoral), Ketoconazole 2% cream (formulation F126)
- Where
- 11 sites in Poland, United Kingdom
- Volunteers
- 583 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Tinea Pedis
Clinical Equivalence of Two Butenafine Hydrochloride 1% Creams in Patients With Interdigital Tinea Pedis
To demonstrate comparable safety and efficacy of Taro Pharmaceuticals Inc. butenafine hydrochloride cream 1% (test product) and Lotrimin Ultra® cream (reference listed drug) in the treatment of interdigital tinea pedis, and to…
- Trial name
- NCT00835510
- Testing
- Butenafine cream 1% manufactured by Taro, Lotrimin Ultra (butenafine) 1%, Butenafine Vehicle manufactured by Taro
- Where
- 17 sites in United States, Belize
- Volunteers
- 548 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Tinea Pedis
A Therapeutic Equivalence Study of Two Oxiconazole Nitrate Topical Cream Treatments for Patients With Tinea Pedis
The objective of this study is to demonstrate that Oxiconazole nitrate 1% topical cream is effective for the treatment of patients with moderate to severe Tinea pedis.
- Trial name
- NCT01519752
- Testing
- Oxiconazole Nitrate Cream 1%, Oxiconazole Nitrate Cream 1% (Oxistat®)
- Volunteers
- 661 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Tinea Pedis
Efficacy and Safety of Terbinafine Film Forming Solution in Patients With Tinea Pedis
This study will compare the efficacy and safety of a single dose of terbinafine film forming solution 1% with a single dose of placebo film forming solution in the treatment of tinea pedis.
- Trial name
- NCT01433107
- Testing
- Terbinafine
- Where
- 6 sites in China
- Volunteers
- 290 people
- Sponsor
- Novartis
Tinea Pedis
Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis
The purpose of this study is to evaluate the efficacy and safety of NAFT-600, applied once daily for 2 weeks, when compared to placebo for 2 weeks in the treatment of subjects with tinea pedis.
- Trial name
- NAFT-600 (NCT01289015)
- Testing
- NAFT-600 ( naftin 2 % gel )
- Where
- 23 sites in United States, Puerto Rico
- Volunteers
- 855 people
- Sponsor
- Merz North America, Inc.